Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 398

1.

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K.

Br J Psychiatry. 2008 Jun;192(6):406-11. doi: 10.1192/bjp.bp.107.037184. Review.

PMID:
18515889
[PubMed - indexed for MEDLINE]
Free Article
2.

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.

Newcomer JW.

CNS Drugs. 2005;19 Suppl 1:1-93. Review.

PMID:
15998156
[PubMed - indexed for MEDLINE]
3.

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.

Citrome L, Jaffe A, Levine J, Allingham B, Robinson J.

Psychiatr Serv. 2004 Sep;55(9):1006-13.

PMID:
15345760
[PubMed - indexed for MEDLINE]
4.

Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies.

Ramaswamy K, Masand PS, Nasrallah HA.

Ann Clin Psychiatry. 2006 Jul-Sep;18(3):183-94. Review.

PMID:
16923657
[PubMed - indexed for MEDLINE]
5.

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM.

Am J Psychiatry. 2009 Feb;166(2):152-63. doi: 10.1176/appi.ajp.2008.08030368. Epub 2008 Nov 17.

PMID:
19015230
[PubMed - indexed for MEDLINE]
6.

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Correll CU, Leucht S, Kane JM.

Am J Psychiatry. 2004 Mar;161(3):414-25. Review.

PMID:
14992963
[PubMed - indexed for MEDLINE]
7.

Assessment of antipsychotic-related risk of diabetes mellitus in a Medicaid psychosis population: sensitivity to study design.

Gianfrancesco F, Pesa J, Wang RH, Nasrallah H.

Am J Health Syst Pharm. 2006 Mar 1;63(5):431-41.

PMID:
16484517
[PubMed - indexed for MEDLINE]
8.

[Schizophrenia, diabetes mellitus and antipsychotics].

Gury C.

Encephale. 2004 Jul-Aug;30(4):382-91. Review. French.

PMID:
15538314
[PubMed - indexed for MEDLINE]
9.

Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics.

Citrome LL, Holt RI, Zachry WM, Clewell JD, Orth PA, Karagianis JL, Hoffmann VP.

Ann Pharmacother. 2007 Oct;41(10):1593-603. Epub 2007 Sep 4. Review.

PMID:
17785613
[PubMed - indexed for MEDLINE]
10.

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis.

Kemmler G, Hummer M, Widschwendter C, Fleischhacker WW.

Arch Gen Psychiatry. 2005 Dec;62(12):1305-12.

PMID:
16330718
[PubMed - indexed for MEDLINE]
11.

Pharmacotherapy and health care costs among patients with schizophrenia and newly diagnosed diabetes.

Leslie DL, Rosenheck RA.

Psychiatr Serv. 2005 Jul;56(7):803-9.

PMID:
16020811
[PubMed - indexed for MEDLINE]
12.

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

Leucht S, Wahlbeck K, Hamann J, Kissling W.

Lancet. 2003 May 10;361(9369):1581-9. Review.

PMID:
12747876
[PubMed - indexed for MEDLINE]
13.

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.

Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S.

Am J Psychiatry. 2006 Feb;163(2):185-94. Review.

PMID:
16449469
[PubMed - indexed for MEDLINE]
14.

Are there any differences in the efficacy among second generation antipsychotics in the treatment of schizophrenia and related disorders?

Motlová L, Spaniel F, Höschl C, Balon R.

Ann Clin Psychiatry. 2007 Apr-Jun;19(2):133-43. Review.

PMID:
17612853
[PubMed - indexed for MEDLINE]
15.

Sleep disturbances in patients with schizophrenia : impact and effect of antipsychotics.

Cohrs S.

CNS Drugs. 2008;22(11):939-62. Review.

PMID:
18840034
[PubMed - indexed for MEDLINE]
16.

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM.

Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6.

PMID:
19058842
[PubMed - indexed for MEDLINE]
17.

Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia.

Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B.

Pharmacogenomics J. 2008 Jun;8(3):228-36. Epub 2007 Aug 28.

PMID:
17726453
[PubMed - indexed for MEDLINE]
18.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
[PubMed - indexed for MEDLINE]
19.

Testing for diabetes in hospitalised patients prescribed antipsychotic drugs.

Taylor D, Young C, Esop R, Paton C, Walwyn R.

Br J Psychiatry. 2004 Aug;185:152-6.

PMID:
15286067
[PubMed - indexed for MEDLINE]
Free Article
20.

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association.

Schizophr Res. 2008 Mar;100(1-3):20-38. doi: 10.1016/j.schres.2007.11.033. Epub 2008 Feb 19. Review.

PMID:
18243663
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk